Intranasal inoculation with human rhinovirus type 2 induced specific antibody responses that peaked at 5 weeks and persisted for at least 1 year, providing protection against reinfection.
Does inoculation with human rhinovirus type 2 induce a specific humoral immune response in volunteers?
HRV-2 infection induces a specific humoral immune response that peaks at 5 weeks and provides protection against reinfection for at least 1 year.
SUMMARY The specific humoral immune response of 17 volunteers to infection with human rhinovirus type 2 (HRV-2) has been measured both by neutralization and by ELISA. Six volunteers who had HRV-2-specific antibodies in either serum or nasal secretions before HRV-2 inoculation were resistant to infection and illness. Of the remaining 11 volunteers who had little pre-existing HRV-2-specific antibody, one was immune but 10 became infected and displayed increases in HRV-2-specific antibodies. These antibodies first increased 1–2 weeks after infection and reached a maximum at 5 weeks. All six resistant volunteers who had high pre-existing antibody and eight of the volunteers who became infected maintained their HRV-2-specific antibody for at least 1 year. At this time they were protected against reinfection. Two volunteers showed decreases in HRV-2-specific antibodies from either serum or nasal secretions. They became infected but not ill after HRV-2 inoculation 1 year later.
Barclay et al. (1989) studied Rhinovirus infection (n=21). Human rhinovirus type 2 (HRV-2) vs. Saline was evaluated on HRV-2-specific antibody response. Intranasal inoculation with human rhinovirus type 2 induced specific antibody responses that peaked at 5 weeks and persisted for at least 1 year, providing protection against reinfection.